中文版English

NEW SOUTH Pharmaceutical's Artequick saved millions of lives in Africa

Meizhou antimalarial drug boardcast on CCTV News

Update: 2017-05-10 10:25:50 Source: MeiZhou Daily Hits:26

 Last night,CCTV News broadcast “Silk Road Renaissance “Share”:To make people more happier and more civilized" which reported China's 800,000 anti-malarial drugs "Artequick" were delivered to West African Republic of Togo since March this year, and quickly cleared malaria. Reporters learned that "Artequick" was produced by Guangdong NEW SOUTH Pharmaceutical Co., Ltd. in Fengshun County.

 The report said that since 2013, China antimalarial drugs quickly enter into Africa along the Belt and Road. At present, the African countries are making full efforts to promote the Chinese artemisinin-based comprehensive malaria control. By 2020, 21 countries worldwide are expected to eliminate malaria.

 It is understood that in 2003, Meizhou businessmen Zhu Layi, president of Guangdong NEW SOUTH Pharmaceutical Co., Ltd.funded expert Professor Li Guoqiao and his artemisinin research team, to promote the scientific research on Artemisia annua. In 2004, with production,operation, research and development, Guangdong New South Science and Technology Co., Ltd. and Guangdong New South Artemisia annua Pharmaceutical Co., Ltd. was set up in Fengshun County, and cooperate with Li Guoqiao and its research team to jointly develop the fourth generation of compound Artemisia annua "Artequick". In 2007, 2012, 2013, Guangdong New South Science and Technology Co., Ltd. has successively started the rapid removal of malaria project with compound artemisinin in the three islands of the Comoros. By 2014, the Comoros achieved zero death from malaria and a 98 per cent reduction in the number of patients.

 Driven by Zhu Layi, artemisinin became the first Chinese original drug receiving world-recognized pharmaceutical patents. New Southern Artemisia annua Pharmaceutical saved millions of the lives in Africa, and has became Meizhou's another "Chinese Business Card".